Gastroenteropancreatic
neuroendocrine tumors (GEP-NETs) raise difficult therapeutic problems despite the emergence of targeted
therapies.
Somatostatin analogs (SSA) remain pivotal therapeutic drugs. However, the tachyphylaxis and the limited antitumoral effects observed with the classical
somatostatin 2 (sst2) agonists (
octreotide and
lanreotide) led to the development of new SSA, such as the pan sst receptor agonist
pasireotide. Our aim was to compare the effects of
pasireotide and
octreotide on cell survival,
chromogranin A (CgA) secretion, and sst2 phosphorylation/trafficking in pancreatic NET (
pNET) primary cells from 15
tumors. We established and characterized the primary cultures of human pancreatic
tumors (
pNETs) as powerful preclinical models for understanding the
biological effects of SSA. At clinically relevant concentrations (1-10 nM),
pasireotide was at least as efficient as
octreotide in inhibiting CgA secretion and cell viability through caspase-dependent apoptosis during short treatments, irrespective of the expression levels of the different sst receptors or the WHO grade of the parental
tumor. Interestingly, unlike
octreotide, which induces a rapid and persistent partial internalization of sst2 associated with its phosphorylation on Ser341/343,
pasireotide did not phosphorylate sst2 and induced a rapid and transient internalization of the receptor followed by a persistent recycling at the cell surface. These results provide the first evidence, to our knowledge, of striking differences in the dynamics of sst2 trafficking in
pNET cells treated with the two SSAs, but with similar efficiency in the control of CgA secretion and cell viability.